Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
Abstract
A major problem facing both physicians and men with metastatic prostate cancer is whether a specific therapy will work. Currently, when a man develops metastatic prostate cancer, a decision needs to be made as to whether a man with advanced prostate cancer may benefit from hormonal drugs that block the activity of the androgen receptor. There are two drugs that have shown to prolong the survival duration of men in this setting and are approved by the Food and Drug Administration. However, at some point, men do not respond to the treatment. For this reason, we need to identify whether certain blood-based biomarkers can serve as measures of clinical benefit in a subgroup of men. Identifying a subgroup who benefits from these drugs may lead to actionable measure and to the development of new therapies. In addition, another unmet need is understanding the variability in response in men with advanced prostate cancer. Our team proposes to identify and validate factors related to men (known as host) and factors related to the cancer (tumor) in order to understand the variability of the disease. Clinical Applications: If these results are validated, then new trials will be conducted to target these biomarkers. Furthermore, by identifying the prognostic factors, they can assist in identifying subgroups of men with particularly good or poor prognoses for whom therapy can be subsequently tailored. These factors can be incorporated into management of patients. We have assembled a team of internationally recognized medical oncologists, a biostatistician, and clinical trialists in prostate cancer who have led the development of several drugs. We are uniquely positioned to leverage existing resources and conduct the proposed analysis that will address the overarching challenges to optimize treatments of men with metastatic prostate cancer over this 3-year Department of Defense IMPACT grant and will combine our institutional resources as leverage to ensure the success of this project. Successful identification of predictive markers for survival will have short- and long-term impacts that will lead to faster access to effective care for men with advanced prostate cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1810278
Entities
People
- Susan Halabi
Organizations
- Duke University
- United States Army